nodes	percent_of_prediction	percent_of_DWPC	metapath
Tyloxapol—LPL—Diseases associated with visual transduction—SAG—ocular cancer	0.0901	0.0901	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—CCND3—ocular cancer	0.0662	0.0662	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—E2F4—ocular cancer	0.0608	0.0608	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—RBL1—ocular cancer	0.0596	0.0596	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—RBL2—ocular cancer	0.0547	0.0547	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—E2F1—ocular cancer	0.0527	0.0527	CbGpPWpGaD
Tyloxapol—LPL—Alzheimers Disease—GNAQ—ocular cancer	0.0461	0.0461	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—CDK2—ocular cancer	0.0455	0.0455	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—RB1—ocular cancer	0.0374	0.0374	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—CDKN1B—ocular cancer	0.0291	0.0291	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—CDK4—ocular cancer	0.0285	0.0285	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—CDKN1A—ocular cancer	0.0268	0.0268	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—EP300—ocular cancer	0.0255	0.0255	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—E2F1—ocular cancer	0.023	0.023	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—MYC—ocular cancer	0.0223	0.0223	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—HRAS—ocular cancer	0.0175	0.0175	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—EP300—ocular cancer	0.0169	0.0169	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—RB1—ocular cancer	0.0163	0.0163	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—CCND3—ocular cancer	0.015	0.015	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—TGFB1—ocular cancer	0.0147	0.0147	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PSPH—ocular cancer	0.0145	0.0145	CbGpPWpGaD
Tyloxapol—LPL—Alzheimers Disease—TP53—ocular cancer	0.0119	0.0119	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—CDKN1A—ocular cancer	0.0117	0.0117	CbGpPWpGaD
Tyloxapol—LPL—Disease—SAG—ocular cancer	0.0114	0.0114	CbGpPWpGaD
Tyloxapol—LPL—SREBP signalling—AKT1—ocular cancer	0.0112	0.0112	CbGpPWpGaD
Tyloxapol—LPL—Disease—E2F5—ocular cancer	0.0101	0.0101	CbGpPWpGaD
Tyloxapol—LPL—Disease—E2F4—ocular cancer	0.00992	0.00992	CbGpPWpGaD
Tyloxapol—LPL—Disease—RPL39—ocular cancer	0.00973	0.00973	CbGpPWpGaD
Tyloxapol—LPL—Disease—RBL1—ocular cancer	0.00973	0.00973	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—TGFB1—ocular cancer	0.00967	0.00967	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SAG—ocular cancer	0.00801	0.00801	CbGpPWpGaD
Tyloxapol—LPL—Disease—TFDP1—ocular cancer	0.00784	0.00784	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—E2F5—ocular cancer	0.00709	0.00709	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—E2F4—ocular cancer	0.00695	0.00695	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—RBL1—ocular cancer	0.00681	0.00681	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—CDK4—ocular cancer	0.00643	0.00643	CbGpPWpGaD
Tyloxapol—LPL—Disease—MAML2—ocular cancer	0.00623	0.00623	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—E2F3—ocular cancer	0.00591	0.00591	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TFDP1—ocular cancer	0.00549	0.00549	CbGpPWpGaD
Tyloxapol—LPL—Disease—HDAC1—ocular cancer	0.00455	0.00455	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GNA11—ocular cancer	0.00455	0.00455	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MAML2—ocular cancer	0.00436	0.00436	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GNAQ—ocular cancer	0.00423	0.00423	CbGpPWpGaD
Tyloxapol—LPL—Disease—CDKN2B—ocular cancer	0.00408	0.00408	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—EP300—ocular cancer	0.00382	0.00382	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GNA11—ocular cancer	0.00381	0.00381	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GNAQ—ocular cancer	0.00354	0.00354	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—EP300—ocular cancer	0.00341	0.00341	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—TGFB1—ocular cancer	0.00332	0.00332	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HDAC1—ocular cancer	0.00319	0.00319	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CDKN2B—ocular cancer	0.00286	0.00286	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—E2F1—ocular cancer	0.00262	0.00262	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—HRAS—ocular cancer	0.00262	0.00262	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—AKT1—ocular cancer	0.00231	0.00231	CbGpPWpGaD
Tyloxapol—LPL—Disease—MDM2—ocular cancer	0.00226	0.00226	CbGpPWpGaD
Tyloxapol—LPL—Disease—CDKN1B—ocular cancer	0.00207	0.00207	CbGpPWpGaD
Tyloxapol—LPL—Disease—CDKN1A—ocular cancer	0.00191	0.00191	CbGpPWpGaD
Tyloxapol—LPL—Disease—EP300—ocular cancer	0.00182	0.00182	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MDM2—ocular cancer	0.00159	0.00159	CbGpPWpGaD
Tyloxapol—LPL—Disease—MYC—ocular cancer	0.00158	0.00158	CbGpPWpGaD
Tyloxapol—LPL—Disease—TGFB1—ocular cancer	0.00158	0.00158	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—EP300—ocular cancer	0.00152	0.00152	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CDKN1B—ocular cancer	0.00145	0.00145	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CCND1—ocular cancer	0.00138	0.00138	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—CDKN1A—ocular cancer	0.00134	0.00134	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—EP300—ocular cancer	0.00127	0.00127	CbGpPWpGaD
Tyloxapol—LPL—Disease—HRAS—ocular cancer	0.00124	0.00124	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MYC—ocular cancer	0.00111	0.00111	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TGFB1—ocular cancer	0.00111	0.00111	CbGpPWpGaD
Tyloxapol—LPL—Disease—AKT1—ocular cancer	0.0011	0.0011	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—AKT1—ocular cancer	0.000919	0.000919	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TP53—ocular cancer	0.00091	0.00091	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HRAS—ocular cancer	0.00087	0.00087	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—AKT1—ocular cancer	0.000768	0.000768	CbGpPWpGaD
